Company intelligence / Profile preview
Alpha-9 Oncology
Boston, Massachusetts, United Statesa9oncology.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Alpha-9 is advancing a clinical pipeline of radiopharmaceuticals with the first patient dosed in a Phase 1 study of A9-3202 for locally advanced or metastatic melanoma in May 2024. The company has secured significant funding to advance its pipeline.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsPeptide-based radiopharmaceuticals
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
ITM Isotope Technologies Munich SENorthStar Medical RadioisotopesActineer Inc.
Beyond the preview
Go deeper on Alpha-9 Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-9 Oncology.